Manufacturer record

Mercury Laboratories Limited: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

11 batches manufactured by Mercury Laboratories Limited (Gujarat) were declared Not of Standard Quality between March 2020 and October 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

11 records linked to Mercury Laboratories Limited in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
11Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Mar 2020 to Oct 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

11
NSQ batches since 2020
4
Products affected
Dissolution
Most common failure
Oct 2025
Latest alert

Flagged batches per year

2020 · 12022 · 72024 · 22025 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Amlodipine Tablets IP 5mg 24110214Mfg 2024-08 · Exp 2027-07 The sample does not conform to the IP with respect to Assay .Assay DTL, JaipurState lab Oct 2025
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP 23112701Mfg 2023-03 · Exp 2025-02 Dissolution of MontelukastDissolution RDTL GuwahatiCDSCO lab Jun 2024
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP 23112703Mfg 2023-03 · Exp 2025-02 Dissolution of MontelukastDissolution RDTL GuwahatiState lab Feb 2024
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP 22112701Mfg 2022-01 · Exp 2023-12 DissolutionDissolution CDL KolkataCDSCO lab Oct 2022
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP 21112704Mfg 2021-05 · Exp 2023-04 Dissolution of MontelukastDissolution RDTL GuwahatiCDSCO lab Aug 2022
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP) 21112704Mfg 2021-05 · Exp 2023-04 DissolutionDissolution CDL KolkataCDSCO lab Jul 2022
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP) 22112701Mfg 2022-01 · Exp 2023-12 DissolutionDissolution CDL KolkataCDSCO lab Jul 2022
Levocetirizine Dihydrochloride & Montelukast Sodium Tablets IP 21112704Mfg 2021-05 · Exp 2023-04 DissolutionDissolution RDTL GuwahatiState lab Jul 2022
Salbutamol Tablets IP 4mg. 21112002Mfg 2021-05 · Exp 2024-04 DisintegrationDisintegration RDTL GuwahatiState lab Jun 2022
Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP 21112701Mfg 2021-01 · Exp 2022-12 DissolutionDissolution RDTL GuwahatiCDSCO lab Apr 2022
Methylergometrine Maleate Tablets IP 19113201Mfg 2019-06 · Exp 2021-05 AssayAssay RDTL ChandigarhCDSCO lab Mar 2020

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.